Comparing Tirzepatide, CPAP and Lifestyle Changes for Sleep Apnea in Older Adults With Overweight
Compares tirzepatide, CPAP and lifestyle changes for sleep apnea in older adults with overweight.
Key facts
- Who runs it
- Institut De Recerca Biomedica De Lleida Fundacio Dr. Pifarre
- Where
- Guadalajara and Lleida, SpainSee the 2 sites
- Trial code
- Registry title
- ObStructive Sleep Apnoea ManageMent in Older AdUlts with Overweight or ObEsity: A Randomized ClinicaL Trial (SAMUEL study)
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 345 people, planned
- Started
- 1 Jul 2026
- Expected to end
- 1 Oct 2028
- Type of study
- Interventional
- Record updated
- 29 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 65 or older with moderate-to-severe obstructive sleep apnoea and overweight or obesity. It compares tirzepatide, CPAP and a lifestyle programme.
- Age
- 65 years or older
- Sex
- All sexes can join
- Disease stage
- Moderate-to-severe obstructive sleep apnoea (Apnea-Hypopnea Index of 15 events/h or more) and Body Mass Index of 27 kg/m2 or more
- Earlier treatment
- Must not have used GLP-1 receptor agonists or GIP/GLP-1 receptor agonists in the 3 months before screening
Main reasons for not taking part
- Type 1 diabetes
- History of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- History of chronic pancreatitis
- Severe kidney impairment (eGFR below 30 mL/min/1.73m2)
- Heart attack or stroke within the last 6 months
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Age >= 65 years
- Clinical diagnosis of moderate-to-severe Obstructive Sleep Apnea (OSA) defined by an Apnea-Hypopnea Index (AHI) >= 15 events/h
- Body Mass Index (BMI) >= 27 kg/m2
- Patients who are candidates for CPAP therapy or lifestyle intervention
- Capable of giving signed informed consent
Who cannot take part
- Previous use of GLP-1 receptor agonists or GIP/GLP-1 receptor agonists within 3 months prior to screening
- Diagnosis of Type 1 Diabetes Mellitus
- History of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- History of chronic pancreatitis
- Major cardiovascular event (infarction, stroke) within the last 6 months
- Any condition that, in the investigator's opinion, prevents the patient from completing the study procedures (e.g., severe cognitive impairment)
- Severe renal impairment (eGFR <30mL/min/1.73m2)
Where in Spain
- Hospital Universitario De Guadalajara SESCAMGuadalajara, SpainNot yet recruiting
- Hospital Universitari de Santa MariaLleida, SpainNot yet recruiting
About the trial
What the trial wants to find out
To determine the best first-line treatment for Obstructive Sleep Apnea (OSA) in older adults (≥65 years) with overweight or obesity by comparing the efficacy of Tirzepatide versus Continuous Positive Airway Pressure (CPAP) and versus an interdisciplinary lifestyle modification intervention, based on the change in the Apnea-Hypopnea Index (AHI) after 24 weeks of treatment.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- ObStructive Sleep Apnoea ManageMent in Older AdUlts with Overweight or ObEsity: A Randomized ClinicaL Trial (SAMUEL study)
- Plain-language title
- Comparing Tirzepatide, CPAP and Lifestyle Changes for Sleep Apnea in Older Adults With OverweightGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 29 June 2026